A Phase 2, Open-Label, Multicenter Study of Zoldonrasib(RMC-9805) in Previously Treated Patients with RAS G12DMutant Non-Small Cell Lung Cancer (NSCLC) – Subprotocol D

2025-521681-10-00 · tracked via the Priya Life Science EU tracker

Sponsor

Revolution Medicines Inc.

Sponsor type

Pharmaceutical company

Therapeutic area

Respiratory Tract Diseases

Decision date

22/09/2025

Enrollment target

Sites

Germany, Greece, Netherlands, Czechia, France, Austria, Denmark, Spain, Italy

Condition studied

Lung Cancer

Investigational medicinal product(s)

RMC-9805

Eligibility

Age group

65+ years, 18-64 years

Sex

Female, Male

Primary endpoint

Confirmed ORR per RECIST v1.1 as assessed by BICR

Endpoint detail

•PFS, • OS, • DOR, • TTR, • DCR, • PFS rate at 6 months and 12 months and OS rate at 12 months, • Incidence of TEAEs, SAEs, and changes from baseline in clinical laboratory values and vital signs., • Zoldonrasib blood concentration over time

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-521681-10-00 on CTIS ↗ ← All trials in the EU